Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245540 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Pau d' Arco in Primary Dysmenorrhea
A Early Phase 1 study, sponsored by National University of Natural Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT04245540 is a Early Phase 1 study that has completed, run by National University of Natural Medicine. The registered enrollment target is 12 participants.
The verdict
NCT04245540, a Early Phase 1 study, has completed, sponsored by National University of Natural Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the hypothesis that Tabebuia avellanedae reduces PGE2 concentration in vivo in women with PDM.
Interventions
- DIETARY_SUPPLEMENT Pau d' Arco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2022-12-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04245540
The ClinicalTrials.gov registry entry for NCT04245540 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National University of Natural Medicine, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pau d' Arco is the first listed.
NCT04245540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04245540 about?
NCT04245540 is a clinical study titled "Effects of Pau d' Arco in Primary Dysmenorrhea". A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect ...
What is the current status of trial NCT04245540?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2019-07-30. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04245540?
The interventions under investigation include: Pau d' Arco (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04245540?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.